Montelucaste Mylan (Montelukast)

Montelukast selectively blocks the cysteinyl leukotriene receptor CysLT1 on airway smooth muscle and inflammatory cells. This inhibition prevents leukotriene‑driven bronchoconstriction, mucus production, and vascular leakage, thereby easing breathing difficulties and allergic symptoms.

The appropriate dose of Montelucaste Mylan is determined by the prescribing clinician based on the patient’s age, weight, and specific indication. Dosage instructions are provided on the prescription label and should be followed exactly as directed.

Montelucaste Mylan is classified as Pregnancy Category B, indicating no evidence of risk in animal studies but limited human data. It is generally considered compatible with breastfeeding, though mothers should discuss any concerns with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Montelucaste Mylan belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is especially useful for patients with aspirin‑sensitive asthma or those who need additional control beyond inhaled therapy, though it does not replace rescue bronchodilators.

Montelucaste Mylan should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing in bathrooms or other humid environments.

Montelucaste Mylan is taken orally, usually once daily in the evening, with or without food. The tablet should be swallowed whole with a glass of water and not chewed or crushed, unless the prescriber provides an alternative formulation.

Serious risks include rare allergic reactions such as angioedema or anaphylaxis, mood changes including depression or suicidal thoughts, and rare skin conditions like Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience any of these symptoms.

Montelucaste Mylan should be avoided in individuals with known hypersensitivity to montelukast or any component of the formulation. It is also not recommended as a sole rescue medication for acute asthma attacks; patients should have a fast‑acting bronchodilator available.